Results 151 to 160 of about 35,320 (249)

Post‐marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data

Headache: The Journal of Head and Face Pain, Volume 66, Issue 5, Page 1128-1147, May 2026.
Abstract Objective Calcitonin gene‐related peptide (CGRP) inhibitors, including monoclonal antibodies (mAbs) and small‐molecule antagonists (gepants), have transformed migraine treatment. Although clinical trials established their efficacy and initial safety, post‐marketing surveillance is essential for understanding their real‐world safety profile in ...
Martina Giacon, Salvatore Terrazzino
wiley   +1 more source

Assessing Research Impact With Bibliometrics and Altmetrics: The Case of the Canadian Network for Observational Drug Effect Studies (CNODES). [PDF]

Pharmacoepidemiol Drug Saf
Yip AM, Sketris IS, Stewart SA, Reynier P, Mongeon P, Filion KB.   +5 more
europepmc   +1 more source

Locum doctor working: A qualitative exploration of the implications for learning and professional development

Medical Education, Volume 60, Issue 5, Page 524-534, May 2026.
Abstract Background In the English National Health Service, and other health care systems internationally, there have been growing numbers of doctors working on a short‐ or long‐term temporary basis as ‘locums’. Social environments and professional relationships are fundamental to learning in clinical contexts; however, locums are often positioned at ...
Jane Ferguson, Gemma Stringer, Kieran Walshe, Thomas Allen, Christos Grigoroglou, Evangelos Kontopantelis, Darren M. Ashcroft   +6 more
wiley   +1 more source

A Methodological Review of Simulation Studies Published in Pharmacoepidemiology and Drug Safety. [PDF]

Pharmacoepidemiol Drug Saf
Muddiman R, Battan FIA, Tazare J, Schultze A, Boland F, Perez T, Wei L, Walsh ME, Moriarty F.   +8 more
europepmc   +1 more source

Correction: Impact of COVID-19 lockdown on methadone and buprenorphine prescriptions in England primary cares: an interrupted time series analysis. [PDF]

Harm Reduct J
Chang YC, Liao WC, Chen LC, Chen TC.
europepmc   +1 more source

Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Mexico: a systematic review. [PDF]

J Comp Eff Res
Ceballos Ruiz C, Navarro A.
europepmc   +1 more source

Strengthening Pharmacoepidemiology in a Changing Research Environment: The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). [PDF]

Pharmacoepidemiol Drug Saf
Kurz X, Cohet C, Perez-Gutthann S, Rao S, Gardarsdottir H.   +4 more
europepmc   +1 more source

Sharing the benefits of genetic research [PDF]

, 2005
Anita Kleinsmidt, Carolina Lasén Lasén Diáz, Dafna Feinholz, Doris Schroeder, Fatima Alvarez-Castillo,, Miltos Ladikas, Udo Schuklenk   +6 more
core   +1 more source

Suitability of Japanese Medical Databases for Studies on Infant Outcomes After Maternal Drug Exposure: An Evaluation Based on Core Data Elements. [PDF]

Pharmacoepidemiol Drug Saf
Hatakeyama S, Sakai T, Tsuchiya M, Kikuchi D, Sato Y, Kondo Y, Sato I, Okada Y, Obara T.   +8 more
europepmc   +1 more source

Pharmacoepidemiology [PDF]

Journal of Epidemiology and Community Health, 1996
openaire   +1 more source